Skip to main content
CPMD
OTC Life Sciences

CannaPharmaRx Q3: $32,037 Cash, $30.9M Working Capital Hole, $9.3M in Arrears

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Healthcare
Sentiment info
Negative
Importance info
8
Price
$0.002
Mkt Cap
$1.417M
52W Low
$0
52W High
$0.01
52W Position info
567% above low
Off High info
80% below high
Rel. Volume info
4.1× avg
Market data snapshot near publication time

CPMD has more than doubled off its 52-week low of $0 on elevated volume (4.1× avg).

Summary

CannaPharmaRx's Q3 2026 net income of $645,416 is purely non-cash mark-to-market gains; operations lost $532,943, and the company holds $32,037 of cash against a $30.9M working capital deficit and roughly $9.3M in arrears.


Key Events · Earnings and Guidance · CPMD

  • Q3 Profit Is Non-Cash Only

    Net income of $645,416 for the three months ended September 30, 2026 came from fair value gains of $1,728,677 on the derivative conversion feature and $181,693 on the obligation to issue shares; the operating loss was $532,943.

  • Liquidity Still Critical

    Cash was $32,037 at September 30, 2026 against a working capital deficiency of $30,929,128 and an accumulated deficit of $113,961,237; nine-month operating cash use was $537,675.

  • Arrears Near $9.3 Million

    Past-due convertible notes, notes payable, royalties and Formosa lease amounts totaled $8,977,357 at September 30, 2026, with total arrears of approximately $9,281,343 as of the report date; a further $20,822,401 is payable on demand or matures December 31, 2026.

  • Revenue Shrinks, One Customer

    Q3 revenue fell to $137,705 from $656,606 a year earlier; related party Cantek represented 87% of the $1,041,385 nine-month revenue.


Analysis · CPMD · Life Sciences

The headline net income of $645,416 is an accounting artifact, not a turnaround. It comes entirely from non-cash fair value gains of $1,728,677 on the derivative conversion feature and $181,693 on the obligation to issue shares, while operations lost $532,943. With cash of $32,037 against a $30,929,128 working capital deficiency and a $113,961,237 accumulated deficit, the company depends on Koze, a related party that has been paying suppliers directly ($1,432,492 in the nine months). Past-due obligations total $8,977,357, with arrears of roughly $9,281,343 as of the report date; the Koze forbearance had already lapsed on August 31, 2026 before being extended to December 31, 2026 in the October 31, 2026 amendment. Revenue is shrinking ($137,705 in Q3 versus $656,606 a year ago), and 87% of nine-month revenue came from Cantek, itself owned by Koze. Separately, termination of Amir Tal's side letter removes his right to appoint three directors, a governance change worth noting alongside the related-party concentration.

How filings like this one have moved

In the 30 days to Nov 15, 2026, 48.2% of the 1980 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.20%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, CPMD was trading at $0.00 on OTC in the Life Sciences sector, with a market capitalization of approximately $1.4M. The 52-week trading range was $0.00 to $0.01. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

CPMD - Latest Insights

CPMD
Aug 18, 2026, 4:50 PM EDT
Filing Type: 10-Q
Importance Score:
9
Price at Filing: $0.0019
Real-time Price: $0.0020 info
Change: +$0.0001 (+5%) info
Market Cap: $1.417M info
CPMD
May 20, 2026, 3:52 PM EDT
Filing Type: 10-Q
Importance Score:
9
Price at Filing: $0.0037
Real-time Price: $0.0020 info
Change: -$0.0017 (-46%) info
Market Cap: $1.417M info